Eli Lilly and

Eli Lilly and Company is a global biopharmaceutical firm focused on discovering, developing, and manufacturing medicines that advance patient care. Founded in 1876 and headquartered in Indianapolis, Lilly's portfolio spans diabetes and obesity, oncology, immunology, neuroscience, and other therapeutic areas. The company invests heavily in R&D, late?stage trials, and biologics manufacturing capacity to meet demand for innovative therapies. Lilly also collaborates with research institutions and biotech partners to accelerate pipelines and expand indications. In commercial markets, the company supports access initiatives, real?world evidence generation, and digital engagement with patients and providers. As of 2024, Lilly employed roughly 47,000 people globally and continued to scale production and supply chains to support growth. Eli Lilly and Company delivers services and products across multiple industries, with a focus on innovation, customer needs, and regulatory compliance. The company engages in strategy development, technological advancement, and partnerships with a wide client base. Through investments in research, infrastructure, and employee development, Eli Lilly and Company supports long-term growth. The company's portfolio spans solutions that address complex demands in an evolving global landscape. As part of its mission, Eli Lilly and Company emphasizes sustainable practices, ethical governance, and resilience. In addition, Eli Lilly and Company has implemented systems to manage risk, security, and operational efficiency.